HMGB1/RAGE蛋白在肾癌中的表达及其临床意义。
Expression of HMGB1/RAGE protein in renal carcinoma and its clinical significance.
作者信息
Qie Guo-Qiang, Wang Chun-Ting, Chu Yu-Feng, Wang Rong
机构信息
Department of Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong University Jinan 250021, P. R. China.
Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong University Jinan 250021, P. R. China.
出版信息
Int J Clin Exp Pathol. 2015 Jun 1;8(6):6262-8. eCollection 2015.
OBJECTIVE
To investigate the expression of high mobility group protein B1 (HMGB1) and its receptor, receptor for advanced glycation end-product (RAGE), in renal cancer tissue and surrounding normal tissue and to analyze the relationship between the expression level of the protein and receptor as well as the clinical pathological characteristics and prognosis in renal cancer patients.
METHODS
A total of 80 renal carcinoma patients who were surgically treated in our hospital from February 2004 to December 2012 were included in this study. Normal paratumoral tissues were collected as a control. All diagnoses were confirmed with a postoperative pathological examination. All patients had complete pathological data. The expression of HMGB1/RAGE proteins in renal cancer tissue and paratumoral tissue was examined using immunohistochemical methods.
RESULTS
The positive expression rate of HMGB1 was 71% in renal cancer tissue, which was significantly higher than that in the paratumoral normal tissue (25%). The positive expression rate of RAGE was 72% in renal cancer tissue, which was significantly higher than that in the paratumoral normal tissue (27%). Further analysis did not indicate a correlation between the positive expression of HMGB1 and RAGE proteins and gender, age and tumor size (P > 0.05), whereas the expression patterns were shown to correlate with tumor differentiation, clinical stage and lymph node metastasis (P < 0.05). The expression of HMGB1 exhibited a significant positive correlation with RAGE level (P < 0.05), the expression of HMGB1/RAGE proteins exhibited a negative correlation with the prognosis of patients, and the five-year survival rate of patients with positive expression was significantly lower than that of patients with negative expression (P < 0.05).
CONCLUSION
HMGB1/RAGE exhibited significantly elevated expression in renal cancer tissues that was closely related to the clinical prognosis of patients; thus, the expression levels may become a new target in the treatment of renal carcinoma.
目的
探讨高迁移率族蛋白B1（HMGB1）及其受体晚期糖基化终末产物受体（RAGE）在肾癌组织及癌旁正常组织中的表达情况，并分析该蛋白及受体表达水平与肾癌患者临床病理特征及预后的关系。
方法
本研究纳入了2004年2月至2012年12月在我院接受手术治疗的80例肾癌患者。收集癌旁正常组织作为对照。所有诊断均经术后病理检查确诊。所有患者均有完整的病理资料。采用免疫组织化学方法检测HMGB1/RAGE蛋白在肾癌组织及癌旁组织中的表达。
结果
HMGB1在肾癌组织中的阳性表达率为71%，显著高于癌旁正常组织（阳性表达率为25%）。RAGE在肾癌组织中的阳性表达率为72%，显著高于癌旁正常组织（阳性表达率为27%）。进一步分析表明，HMGB1和RAGE蛋白的阳性表达与性别、年龄及肿瘤大小之间无相关性（P>0.05），而其表达模式与肿瘤分化、临床分期及淋巴结转移相关（P<0.05）。HMGB1的表达与RAGE水平呈显著正相关（P<0.05），HMGB1/RAGE蛋白的表达与患者预后呈负相关，阳性表达患者的五年生存率显著低于阴性表达患者（P<0.05）。
结论
HMGB1/RAGE在肾癌组织中的表达显著升高，且与患者临床预后密切相关；因此其表达水平可能成为肾癌治疗的新靶点。
Zotero 插件